Search clinical trials for: JNJ-63623872,

Total 872 results

Janssen Research & Development, LLC

Completed

A Study of JNJ-64565111 After Single Subcutaneous Administration at Different Injection Sites in Otherwise Healthy Overweight/Obese Adult Participants and a Study of JNJ-6456511 in Otherwise Healthy Obese Adult Participants After Multiple Dose

Obesity

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Research Study of JNJ-26854165 to Determine the Safety and Dose in Patients With Advanced Stage or Refractory Solid Tumors.

Neoplasms
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-38431055 in Healthy Male Volunteers

Diabetes Mellitus, Type 2
Chengappa, K.N. Roy, MD
National Institutes of Health (NIH)

Completed

Test of Novel Drug for Smoking Cessation (UH3-P2)

Smoking Cessation

United States
Janssen R&D Ireland

Terminated

A Study of the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of JNJ-47910382 at Different Doses and Dose Regimens in Asian Genotype-1, Chronic, HCV-Infected Patients

Chronic Hepatitis C Infection

Taiwan
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-87189401 Plus JNJ-78278343 for Advanced Prostate Cancer

Advanced Prostate Cancer

France, United States
Janssen Research & Development, LLC

Completed

A Study to Assess the Relative Bioavailability of JNJ64041575 Administered as 2 Different New Concept Formulations (Oral Suspension and Tablet) Compared to Their Respective Current Formulations, and to Assess the Effect of Food on the Pharmacokinetics of the 2 New Concept Formulations

Healthy

Belgium
Janssen Cilag N.V./S.A.

Completed

Study to Investigate Effects of Repeated Administration of Itraconazole on Pharmacokinetics of JNJ-42847922 in Healthy Male Participants

Healthy

Germany
Janssen Research & Development, LLC

Withdrawn

A Dose Range Finding Study of JNJ-39758979 in Patients With Active Rheumatoid Arthritis Currently Treated With Methotrexate

Active Rheumatoid Arthritis; Rheumatoid Arthritis
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42721458 in Healthy Male Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

Study to Evaluate Efficacy, Safety and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder Without Psychiatric Comorbidity

Insomnia

Germany, United States, Netherlands
Janssen Research & Development, LLC

Completed

A Pharmacokinetic Interaction Study Between JNJ-54861911 and Transporter Substrates Rosuvastatin and Metformin in Healthy Participants

Healthy

Germany
Janssen Pharmaceutical K.K.

Completed

Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma

Lymphoma, Mantle-cell

Japan
Janssen-Cilag International NV

Completed

Pilot Study to Evaluate the Duration of Effects on Simulated Car Driving and Cognitive Performance After a Single Dose of JNJ-42847922, Zolpidem and Placebo in Healthy Participants

Healthy

Netherlands
Janssen Research & Development, LLC

Completed

A Study to Evaluate Safety and Efficacy of Toreforant (JNJ-38518168) in Participants With Moderate to Severe Plaque-type Psoriasis

Psoriasis

United States, Poland
Janssen Research & Development, LLC

Completed

Pharmacokinetic, Safety, and Tolerability Study of Intranasally Administered Esketamine in Elderly and and Healthy Younger Adult Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Mass Balance Study With a Microtracer Dose of 14C-esketamine in Healthy Male Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study to Investigate the Effect of Increased Gastric pH on the Oral Bioavailability of the Orexin-2 Receptor Antagonist JNJ-42847922 in Healthy Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of JNJ-64179375 in Healthy Japanese Participants

Healthy

Japan, United Kingdom
Janssen Research & Development, LLC

Completed

A Study of JNJ-42847922 (Seltorexant) in Healthy Participants

Healthy

Netherlands
Janssen Sciences Ireland UC

No longer available

Pre-Approval Access to JNJ-53718678 for the Treatment of Respiratory Syncytial Virus (RSV) Infection in (a) Immunocompromised Adult and Pediatric Participants

Respiratory Syncytial Virus
Janssen Research & Development, LLC

Completed

A Study of Seltorexant in Healthy Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study to Investigate the Antidepressant Mechanism-of-action of JNJ-42847922 in Participants With Major Depressive Disorder

Depressive Disorder, Major

Belgium, United Kingdom, Germany, United States, Netherlands
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of an Intravenous Solution of JNJ-39588146 or Placebo in Patients With Heart Failure

Heart Failure

Belgium, Germany, Poland, Romania
Janssen Research & Development, LLC

Terminated

A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer

Advanced Cancer

United States
Janssen Research & Development, LLC

Recruiting

A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-10)

Relapsed or Refractory Multiple Myeloma

Korea, Republic of, United States, Australia
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis (ANTHEM-UC)

Colitis, Ulcerative

Korea, Republic of, Canada, United States, Australia, Malaysia, Germany, Turkey, Japan, Belgium, Hungary, Italy, Spain, China, Poland, United Kingdom, Brazil, France, Argentina, Czechia, Romania, India
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-64281802 for the Prevention of Dengue Infection

Dengue

Mexico, Brazil, Malaysia, Colombia, Puerto Rico, Panama, Peru, Philippines, Thailand
Janssen Research & Development, LLC

Recruiting

A Study of Apalutamide in Participants With Severe Hepatic Impairment Compared With Participants With Normal Hepatic Function

Hepatic Impairment

United States
Janssen Research & Development, LLC

Completed

A Study of JNJ-67484703 in Participants With Active Rheumatoid Arthritis

Rheumatoid Arthritis

Spain, United States, Hungary, Georgia, Moldova, Republic of, Ukraine
University of Oxford
Janssen Pharmaceutica

Terminated

MIcroglial Colony Stimulating Factor-1 Receptor (CSF1R) in Alzheimer's Disease (MICAD)

Alzheimer Disease | Mild Cognitive Impairment

United Kingdom
Janssen Research & Development, LLC

No longer available

Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

Belgium, Iceland, Portugal, Slovenia
Janssen Research & Development, LLC

Approved for marketing

Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

Brazil, Germany, Italy, Netherlands, Romania, Switzerland, United Kingdom
Janssen Research & Development, LLC

Completed

A Single and Multiple Ascending Dose Study of Subcutaneously Administered JNJ-75220795

Fatty Liver Disease

United States
Janssen Research & Development, LLC

Terminated

Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64565111 in Type 2 Diabetes Mellitus (T2DM)

Diabetes Mellitus, Type 2

Germany
Janssen Research & Development, LLC

Completed

A Study of JNJ-64251330 in Participants With Familial Adenomatous Polyposis

Adenomatous Polyposis Coli

United States, Germany, Korea, Republic of, France, Netherlands, Spain, Puerto Rico
Janssen Research & Development, LLC

Approved for marketing

Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients

Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC

Terminated

A Study of JNJ-66525433 in Healthy Participants and Participants With Ulcerative Colitis

Healthy | Colitis, Ulcerative

Germany
Janssen Research & Development, LLC

Terminated

A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Erdafitinib

Hepatic Impairment

Germany
Janssen-Cilag International NV

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-48816274

Healthy

United Kingdom
Janssen Pharmaceutical K.K.

Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Subcutaneous Injection of JNJ-64304500 in Healthy Japanese and Caucasian Male Participants

Healthy

Japan
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-39393406 in Healthy Participants

Healthy

Belgium
Johnson & Johnson Pharmaceutical Research & Development...

Completed

An Exploratory Study to Assess the Effects of JNJ-39439335 on the Relief of Pain Using a Thermal-Grill Experimental Model

Pain
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of Solid Formulations of JNJ-39393406 in Healthy Male Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study to Investigate the Absorption, Metabolism, and Excretion of JNJ-38518168 After a Single Oral Dose in Healthy Male Participants.

Healthy

Belgium
Janssen-Cilag International NV

Completed

A Study to Investigate P2X7 Receptor Occupancy by JNJ-54175446 With the Newly Developed P2X7 Receptor Positron Emission Tomography (PET) Tracer 18F-JNJ-64413739

Healthy

Belgium
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A First-in-Human Study of JNJ-28431754 in Healthy Male Volunteers

Healthy
Janssen Sciences Ireland UC

Completed

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ 53718678 in Healthy Japanese Adult Participants

Healthy

United Kingdom
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Lymphoma, Non-Hodgkin | Relapsed B-cell NHL | Refractory B-Cell NHL

Turkey
Janssen Research & Development, LLC
City of Hope Medical Center

Recruiting

A Study of JNJ-90014496 in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

United States, Australia, Denmark

3

Subscribe